21.8 C
New York
Wednesday, June 10, 2026

Tag: tablet

newssourceFORcompanyinformationcontent1marketreleases

Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results

LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL re-launched and commercial sales ongoing  

Health and Wellness Market Size Worth USD 11 Trillion by 2034

The health and wellness market size is expected to be worth over USD 11 trillion by 2034, increasing from USD 6.57 trillion in 2024, with a CAGR of 5.50%. The market of health and wellness is driven by rising health awareness, an aging population, technological advancements, growing health consciousness, and supportive government initiatives. 
The health and wellness market size is expected to be worth over USD 11 trillion by 2034, increasing from USD 6.57 trillion in 2024, with a CAGR of 5.50%. The market of health and wellness is driven by rising health awareness, an aging population, technological advancements, growing health consciousness, and supportive government initiatives.

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

Crypto Casinos 2025: JACKBIT Casino Expands Real Money Games Portfolio and Enhances Fast, Instant Withdrawal System

Industry analysis confirms that Jackbit’s no-KYC policy and expansive library of over 7,000 casino games continue to drive strong player demand—reinforced by its growing popularity among members of the Reddit gambling community. 
Industry analysis confirms that Jackbit’s no-KYC policy and expansive library of over 7,000 casino games continue to drive strong player demand—reinforced by its growing popularity among members of the Reddit gambling community.

DIGITAL HEALTH LEADER JMIR PUBLICATIONS ANNOUNCES ITS 2025 IMPACT FACTOR RESULTS

The JMIR Publications portfolio of journals now includes 21 journals with a Journal Impact Factor, with several journals achieving significant year-over-year increases and special distinctions. TORONTO,...

Online Casinos Canada 2025: RoboCat Inaugurates New Online Slots and Instant Games

As Part of the Brand’s Ongoing Efforts for Remaining a Best Choice Amongst All The Online Casinos Canada, RoboCat Has Renovated Their Online Slots and Instant Games Sections with New Titles and Exclusive Bonuses 
As Part of the Brand’s Ongoing Efforts for Remaining a Best Choice Amongst All The Online Casinos Canada, RoboCat Has Renovated Their Online Slots and Instant Games Sections with New Titles and Exclusive Bonuses

Quorum Federal Credit Union Introduces Two New Checking Accounts

Get paid 5 days early with QFlex Checking; earn a competitive rate with QBoost Checking! PURCHASE, N.Y., June 18, 2025 /PRNewswire/ -- Quorum, a recognized...

Ascletis Announces First Participants Dosed in U.S. Phase I Clinical Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor for the Treatment...

-  The Phase I trial evaluates the safety, tolerability and preliminary efficacy of ASC50 for the treatment of psoriasis.-  Preclinical data, including higher oral...

Chronic Hepatitis B Market–The US to Have the Lion’s Share Among the 7MM, Predicts DelveInsight

The chronic hepatitis B market size is predicted to surge owing to the increasing prevalence of the disease globally and rising awareness about early...

Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting

- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications -

ALK’s tablet mod træpollenallergi godkendt til allergivaccination af børn fra fem år

Lægemiddelstyrelsen har netop godkendt Itulazax, den første tabletbaserede allergivaccination til behandling af børn og unge i alderen fem til 17 år med træpollenallergi i Danmark.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTablet

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers